P825: FACTOR D INHIBITION WITH ORAL BCX9930 MONOTHERAPY LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA NAÏV...

por McDonald, A., Malherbe, J. L. R., Kulasekararaj, A., Füreder, W., Griffin, M., Cornpropst, M., Farmer, M. K., Kargl, D., Collins, D., Sheridan, W., Risitano, A.
Publicado 2022

P813: EFFICACY, TREATMENT ADMINISTRATION SATISFACTION AND SAFETY OF SUBCUTANEOUS RAVULIZUMAB THROUGH 1 YEAR IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO RECEIVED PRIOR...

por Yenerel, M. N., Sicre de Fontbrune, F., Piatek, C., Sahin, F., Füreder, W., Ogawa, M., Tomazos, I., Doll, H., Ozol-Godfrey, A., Sierra, J. R., Szer, J.
Publicado 2022

P826: FACTOR D INHIBITION WITH ORAL BCX9930 LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA INADEQUATELY CON...

por Kulasekararaj, A., Füreder, W., McDonald, A., Malherbe, J. L. R., Gandhi, S., Collins, D., Cornpropst, M., Dobo, S., Farmer, M. K., Kargl, D., Sheridan, W., Griffin, M., Risitano, A.
Publicado 2022